Download the Q&A
This article presents an insightful conversation with Dr Irene Rossi on the subject of Nasal Drug Product Development. It delves into the current trends and technical challenges associated with nasal drug formulation. The discussion emphasizes the growing recognition of ‘Nose-to-Brain’ delivery as a promising method to tackle disorders of the brain and central nervous system (CNS). This method offers high bioavailability to the CNS/brain with low systemic blood concentration, potentially leading to effective therapeutic performance with minimal side effects. The article also highlights the success of rapid rescue remedies that utilize the abundant vasculature of the nasal cavity for quick onset, comparable to intravenous drug delivery. The conversation further explores formulation and development challenges, the rapid advancements in delivering small and large proteins, antibodies, vaccines, and even mRNA. The potential of nasal vaccines for respiratory viruses and other illnesses such as HIV is also discussed. Looking forward, the article suggests that nasal drug delivery could play a significant role in treating diseases like dementia and Parkinson’s.
